Dr. Flinn on Toxicities With Venetoclax Plus Obinutuzumab in CLL

Ian Flinn, MD
Published: Wednesday, Feb 14, 2018



Ian Flinn, MD, director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses the toxicities associated with the combination of venetoclax (Venclexta) and obinutuzumab (Gazyva) in chronic lymphocytic leukemia (CLL).

In a study of safety, efficacy, and minimal residual disease (MRD) negativity of the combination of venetoclax and obinutuzumab, patients with previously untreated CLL demonstrated unprecedented MRD negative rates compared to chemo-immunotherapy regimens. The combination was well tolerated, with a favorable benefit/risk profile.

Although there were some toxicities, they did not seem to be synergistic, Flinn says. The most common toxicity in this trial was neutropenia, but that is commonly seen with single-agent venetoclax and is easily manageable. One concern with venetoclax is tumor lysis syndrome, which can be a fatal complication of therapy. There was no clinical evidence of tumor lysis syndrome in this trial, Flinn says.
SELECTED
LANGUAGE


Ian Flinn, MD, director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses the toxicities associated with the combination of venetoclax (Venclexta) and obinutuzumab (Gazyva) in chronic lymphocytic leukemia (CLL).

In a study of safety, efficacy, and minimal residual disease (MRD) negativity of the combination of venetoclax and obinutuzumab, patients with previously untreated CLL demonstrated unprecedented MRD negative rates compared to chemo-immunotherapy regimens. The combination was well tolerated, with a favorable benefit/risk profile.

Although there were some toxicities, they did not seem to be synergistic, Flinn says. The most common toxicity in this trial was neutropenia, but that is commonly seen with single-agent venetoclax and is easily manageable. One concern with venetoclax is tumor lysis syndrome, which can be a fatal complication of therapy. There was no clinical evidence of tumor lysis syndrome in this trial, Flinn says.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Rapid Reviews in Oncology®: Practice-Changing Data in Acute Myeloid Leukemia: A Rapid Update From Atlanta OnlineDec 21, 20182.0
Community Practice Connections™: 2nd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesDec 30, 20182.0
Publication Bottom Border
Border Publication
x